Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987396) titled 'Clinical Investigation to Assess the Effect of Betaglucan Administration in HPV Patients' on May 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Vitae Health Innovation

Condition: HPV

Intervention: Dietary Supplement: 1000 mg Betaglucans (daily)

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: May 15, 2023

Target Sample Size: 80

Countries of Recruitment: Spain

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06987396

Published ...